Details of Disease

General Information of Disease (ID: DISDS5OT)

• Disease Name: Carcinoid syndrome
• Synonyms: carcinoid tumour syndrome; carcinoid tumor syndrome; carcinoid tumors, intestinal; malignant carcinoid syndrome; carcinoid syndrome
• Disease Class: 5B10: Carcinoid syndrome
• Disease Hierarchy:
  DIS6SVEE: Syndromic disease
  DISYKSRF: Genetic disease
  DISDS5OT: Carcinoid syndrome
• ICD Code:
  ICD-11: ICD-11: 5B10
  ICD-10: ICD-10: E34.0
  Expand ICD-11: '5B10
  Expand ICD-10: 'E34.0
• Disease Identifiers:
  MONDO ID: MONDO_0100347
  MESH ID: D008303
  UMLS CUI: C0024586
  MedGen ID: 6191
  Orphanet ID: 100093
  SNOMED CT ID: 35868009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Dopamine	DMPGUCF	Approved	Small molecular drug	[1]
Octreotide	DMHIDCJ	Approved	Small molecular drug	[2]
Telotristat ethyl	DMDIYFZ	Approved	Small molecular drug	[3]

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BIM23A760	DM6EIZG	Phase 2	Small molecular drug	[4]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
REV-598	DM314CZ	Terminated	NA	[5]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SOMATOSTATIN	DMIOFQE	Investigative	NA	[6]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
GUCY2C	TTLDPRG	Limited	Biomarker	[7]
PPY	TTIB95A	Limited	Biomarker	[8]
UCP3	TT12RJK	Limited	Altered Expression	[9]
SDHD	TTVH9W8	Strong	Genetic Variation	[10]
SST	TTWF7UG	Strong	Biomarker	[11]

This Disease Is Related to 2 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
NLRP12	OTGR132Z	Limited	Genetic Variation	[12]
PTPRF	OTH5KF2D	Strong	Biomarker	[13]

References

• [1] Dopamine FDA Label
• [2] Octreotide FDA Label
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819)
• [6] Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes. 2018 Feb;25(1):22-35.
• [7] The paracrine hormone hypothesis of colorectal cancer.Clin Pharmacol Ther. 2007 Oct;82(4):441-7. doi: 10.1038/sj.clpt.6100325. Epub 2007 Aug 8.
• [8] Pancreatic endocrine tumors: recent advances.Ann Oncol. 1999;10 Suppl 4:170-6.
• [9] Metabolome analysis of the serotonin syndrome rat model: Abnormal muscular contraction is related to metabolic alterations and hyper-thermogenesis.Life Sci. 2018 Aug 15;207:550-561. doi: 10.1016/j.lfs.2018.06.031. Epub 2018 Jul 2.
• [10] Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas.Genes Chromosomes Cancer. 2002 Jul;34(3):325-32. doi: 10.1002/gcc.10081.
• [11] Current best practice in the management of neuroendocrine tumors.Ther Adv Endocrinol Metab. 2018 Oct 31;10:2042018818804698. doi: 10.1177/2042018818804698. eCollection 2019.
• [12] Generalized Cytokine Increase in the Setting of a Multisystem Clinical Disorder and Carcinoid Syndrome Associated with a Novel NLRP12 Variant.Dig Dis Sci. 2019 Aug;64(8):2140-2146. doi: 10.1007/s10620-019-05525-6. Epub 2019 Feb 20.
• [13] Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors.Int J Endocrinol. 2018 Jul 2;2018:8126087. doi: 10.1155/2018/8126087. eCollection 2018.